AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02949115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70 mL red beetroot juice without nitrate
Description: 1x daily intake of 70 mL red beetroot juice without nitrate
Study NCT02949115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70 mL placebo drink plus potassium nitrate
Description: 1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
Study NCT02949115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 70 mL placebo drink
Description: 1x daily intake of 70 mL placebo control drink
Study NCT04729088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Description: Intra-anal application performed by the study physician of 2 g of the study drug
Study NCT03541512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + Education
Description: Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health.
Study NCT03541512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health.
Study NCT01100307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: Intravitreal injection of 0.3 mg every 6 weeks
Study NCT01100307 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham injection every 6 weeks
Study NCT02241746 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT00441558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin
Description: flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
Study NCT01247220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.5 mg
Study NCT01247220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.5 mg
Study NCT01247220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Laser
Description: Angiography-directed peripheral laser
Study NCT00918476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filibuvir + Oral Contraceptives
Description: This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
Study NCT02572830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Bilateral Eye Movements
Description: Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
Study NCT02572830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Undelayed Bilateral Eye Movement
Description: Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
Study NCT02918188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
Study NCT02310971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVac
Description: Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
Study NCT01899404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT, DWI, DCE-MRI
Description: All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
Study NCT00435032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early appendectomy
Description: Appendectomy within 24 hours of admission
Study NCT00435032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interval appendectomy
Description: Initial antibiotic treatment followed by appendectomy at 6-8 weeks
Study NCT02627131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study NCT03838172 — intervention group
Intervention type: OTHER
Intervention: Family impact scale
Description: The family Impact Scale (FIS) will be completed by the parents
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study NCT03360344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cock up Splint and Lumbrical exercises
Description: A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
Study NCT03575598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
Study NCT03575598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Study NCT03484897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P927 - LICHTENA DermAD CREMA CORPO
Description: The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
Study NCT02116023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavored beverage
Study NCT02116023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage
Study NCT05975424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Observational study; annual MRI for first 5 years only to monitor changes in the injection site
Study NCT01055340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV
Study NCT01055340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV
Study NCT01055340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV
Study NCT03247101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miyarisan-BM (Clostridium Butyricum Miyairi)
Description: 40mg po tid x 6months
Study NCT03247101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso group
Description: ursodoxycholic acid, 200mg po tid x 6 months
Study NCT03247101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotase group
Description: Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
Study NCT01930500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual neuropsychological rehabilitation
Description: Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
Study NCT01930500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based neuropsychological rehabilitation
Description: Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
Study NCT04876287 — intervention group
Intervention type: DRUG
Intervention: Radioiodine
Description: cancer therapy
Study NCT02489279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Attention Control (SAC) Method
Description: Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
Study NCT02489279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scrabble
Description: Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
Study NCT03446690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MI Varnish
Description: MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
Study NCT03446690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants received routine treatment and oral hygiene regimes. No intervention for this group.
Study NCT02101255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360
Study NCT02101255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Application on Day 0, Day 180, Day 360, Day 540
Study NCT00973128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF plus Antimony reduced dose
Description: 400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
Study NCT00973128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: 20mg/daily for 20 days
Study NCT00497497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: (Only for patients not previously treated with bevacizumab) Intravenous repeating dose
Study NCT00497497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Intravenous repeating dose
Study NCT00497497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Intravenous repeating dose
Study NCT00497497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intravenous repeating dose
Study NCT00497497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study NCT01344356 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: 14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
Study NCT01344356 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy
Description: 8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
Study NCT01943227 — intervention group
Intervention type: OTHER
Intervention: controlled positive pressure ventilation 9ml/kg tidal volume
Description: controlled positive pressure ventilation 9ml/kg tidal volume
Study NCT01943227 — intervention group
Intervention type: OTHER
Intervention: controlled positive pressure ventilation 6ml/kg tidal volume
Description: controlled positive pressure ventilation 6ml/kg tidal volume
Study NCT04120467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity.
Study NCT04120467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
Study NCT04120467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
Study NCT01096004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: oral suspension, 1200mg, once daily, for 10 days
Study NCT01096004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02834364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg p.o. once daily. One cycle is defined as 28 days
Study NCT02834364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg p.o. twice daily. One cycle is defined as 28 days
Study NCT03859219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Study NCT03859219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Study NCT01750554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate-acting digital nerve block
Description: non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
Study NCT01729819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended release capsules
Study NCT01729819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine tartrate extended release capsules
Study NCT03463655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cirrhotic albumin
Description: Ascites puncture
Study NCT03463655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum albumin
Description: blood punctures
Study NCT03682367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin peri- and post-operatively.
Study NCT03682367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Use of sugar-free Placebo peri- and post-operatively.
Study NCT00123630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
Study NCT00123630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV once every 2-4 weeks based on weight
Study NCT00760760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)
Description: 4g daily, 8 weeks
Study NCT00760760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: equivalent amount of fat as butter
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study NCT00916123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study NCT03091855 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
Study NCT03091855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
Study NCT02998307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR Training
Description: Brief CPR assessment and training done during working hours with real-time performance feedback
Study NCT04111575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy
Study NCT01227317 — intervention group
Intervention type: OTHER
Intervention: Prognostic value of Biomarkers
Description: Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
Study NCT04627246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)
Description: SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years.
Study NCT03519178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing
Study NCT03519178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 1
Description: Endocrine Therapy 1
Study NCT03519178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 2
Description: Endocrine Therapy 2
Study NCT01599195 — intervention group
Intervention type: DEVICE
Intervention: AudioDoc
Description: AudioDoc will be used to identify the carotid and femoral bruit
Study NCT04118504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Lifestyle intervention on through mobile application